| Assessment Status | Rapid Review Complete |
| HTA ID | 20023 |
| Drug | Indacterol/glycopyrronium/mometasone furoate |
| Brand | Enerzair® |
| Indication | As a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting β2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year. |
| Assessment Process | |
| Rapid review commissioned | 13/05/2020 |
| Rapid review completed | 10/06/2020 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that indacterol/glycopyrronium/mometasone furoate (Enerzair®) be considered for reimbursement* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
The HSE has approved reimbursement; November 2020
